-
At Axis-Shield, innovation is fundamental to our business. There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. -
Identifying these diseases quickly and efficiently, where possible at the point of care, can be vital in maintaining a patient's quality of life. -
New drug treatments are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy. -
We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
Latest News
3-11-2011
Axis-Shield de-listed from the LSE and OSE on November 22, as a result of its acquisition by Alere
Afinion
Afinion is a new concept
in Point of Care - a multi-parameter rapid analyser system with minimal user input...
NycoCard
Axis-Shield's most widely
distributed product range is particularly suited to countries with developing healthcare systems...
Proprietary Markers
In the laboratory sector
we specialise in proprietary markers for early diagnosis and management of critical illnesses....
OEM
Axis-Shield produces
its own-labelled assays on the AxSYM system and OEM products for global partners including Abbott...
AXIS-SHIELD COMPANIES
